bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Authors: Borger Darrell R. , Goyal Lipika , Yau Thomas , Poon Ronnie T. , Ancukiewicz Marek , Deshpande Vikram , Christiani David C. , Liebman Hannah M. , Yang Hua , Kim Hyeryun , Yen Katharine , Faris Jason E. , Iafrate A. John , Kwak Eunice L. , Clark Jeffrey W. , Allen Jill N. , Blaszkowsky Lawrence S. , Murphy Janet E. , Saha Supriya K. , Hong Theodore S. , Wo Jennifer Y. , Ferrone Cristina R. , Tanabe Kenneth K. , Bardeesy Nabeel , Straley Kimberly S. , Agresta Sam , Schenkein David P. , Ellisen Leif W. , Ryan David P. , Zhu Andrew X.
Published: April 2023

PDF file - 104KB, Clinical features of IDH1-mutant intrahepatic cholangiocarcinoma patients in the Screening cohort.
Supplementary Table 4 from CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
Authors: Cleven Arjen H.G. , Derks Sarah , Draht Muriel X.G. , Smits Kim M. , Melotte Veerle , Van Neste Leander , Tournier Benjamin , Jooste Valerie , Chapusot Caroline , Weijenberg Matty P. , Herman James G. , de Bruïne Adriaan P. , van Engeland Manon
Published: April 2023

Correlations between promoter CpG island methylation of 19 tumor suppressor/DNA repair genes, MSI, BRAF, KRAS and CIMP in the study population.
Supplementary Table 3 from CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
Authors: Cleven Arjen H.G. , Derks Sarah , Draht Muriel X.G. , Smits Kim M. , Melotte Veerle , Van Neste Leander , Tournier Benjamin , Jooste Valerie , Chapusot Caroline , Weijenberg Matty P. , Herman James G. , de Bruïne Adriaan P. , van Engeland Manon
Published: April 2023

CIMP and CL1, CL2 and CL3 in relation to clinicopathological characteristics of the study population.
Supplementary Figure 7 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 37K, Estradiol-17β-D-glucuronide transport in HEK293 OATP1B1 variant cells.
Supplementary Figure 6 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 143K, Influence of Oatp1b2-deficiency on sorafenib N-oxide formation ex vivo.
Supplementary Table 1 from CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer
Authors: Cleven Arjen H.G. , Derks Sarah , Draht Muriel X.G. , Smits Kim M. , Melotte Veerle , Van Neste Leander , Tournier Benjamin , Jooste Valerie , Chapusot Caroline , Weijenberg Matty P. , Herman James G. , de Bruïne Adriaan P. , van Engeland Manon
Published: April 2023

Primer sequences and PCR conditions.
Supplementary Figure 3 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 863K, Influence of Oatp-deficiency on sorafenib, sorafenib N-oxide, and total active compound (sorafenib + N-oxide) pharmacokinetics.
Supplementary Figure 1 from Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Authors: Garrett Joan T. , Sutton Cammie R. , Kuba María Gabriela , Cook Rebecca S. , Arteaga Carlos L.
Published: April 2023

PDF file - 110K, Dose responsiveness of U3-1287 to downregulation of HER3
Supplementary Figure Legends from Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
Authors: Kaneko Naoki , Mitsuoka Keisuke , Amino Nobuaki , Yamanaka Kentaro , Kita Aya , Mori Masamichi , Miyoshi Sosuke , Kuromitsu Sadao
Published: April 2023

PDF file - 63KB
CCR Translation for This Article from miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Authors: Matthaei Hanno , Wylie Dennis , Lloyd Maura B. , Dal Molin Marco , Kemppainen Jon , Mayo Skye C. , Wolfgang Christopher L. , Schulick Richard D. , Langfield Laura , Andruss Bernard F. , Adai Alex T. , Hruban Ralph H. , Szafranska-Schwarzbach Anna E. , Maitra Anirban
Published: April 2023

CCR Translation for This Article from miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Supplementary Figure Legends from CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Authors: Swarts Dorian R.A. , Henfling Mieke E.R. , Van Neste Leander , van Suylen Robert-Jan , Dingemans Anne-Marie C. , Dinjens Winand N.M. , Haesevoets Annick , Rudelius Martina , Thunnissen Erik , Volante Marco , Van Criekinge Wim , van Engeland Manon , Ramaekers Frans C.S. , Speel Ernst-Jan M.
Published: April 2023

PDF file - 71K
Supplementary Figure Legend from The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Authors: Jiang Xiaofeng , Zhou Jun , Giobbie-Hurder Anita , Wargo Jennifer , Hodi F. Stephen
Published: April 2023

PDF file - 68K
Supplementary Figure 3 from CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Authors: Swarts Dorian R.A. , Henfling Mieke E.R. , Van Neste Leander , van Suylen Robert-Jan , Dingemans Anne-Marie C. , Dinjens Winand N.M. , Haesevoets Annick , Rudelius Martina , Thunnissen Erik , Volante Marco , Van Criekinge Wim , van Engeland Manon , Ramaekers Frans C.S. , Speel Ernst-Jan M.
Published: April 2023

PDF file - 1346K, Kaplan-Meier analysis showing 20-year overall survival rates for a combined group of carcinoids and high-grade neuroendocrine carcinomas. A gradient of OTP immunostaining is shown for the 312 out of 348 cases with available follow-up. The solid lines indicate cases with nuclear staining which may or may not display cytoplasmic immunoreactivity, the dashed lines indicate tumors which have lost nuclear staining but retain cytoplasmic positivity, and the dotted lines indicate negative tumors. The period is indicated in months. Censored cases are indicated by an asterisk.
Supplementary Figure 3 from The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Authors: Jiang Xiaofeng , Zhou Jun , Giobbie-Hurder Anita , Wargo Jennifer , Hodi F. Stephen
Published: April 2023

PDF file - 53K, Decreases in phospo-ERK1/2 to U0126 treatment
Supplementary Figure 1 from CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Authors: Swarts Dorian R.A. , Henfling Mieke E.R. , Van Neste Leander , van Suylen Robert-Jan , Dingemans Anne-Marie C. , Dinjens Winand N.M. , Haesevoets Annick , Rudelius Martina , Thunnissen Erik , Volante Marco , Van Criekinge Wim , van Engeland Manon , Ramaekers Frans C.S. , Speel Ernst-Jan M.
Published: April 2023

Representative immunohistochemical staining patterns for CD44 (A), OTP (B) and RET (C). (A) Normal lung tissue adjacent to a carcinoid tumor showing CD44 staining of the bronchial epithelium BE and seromucous glands G (original magnification 100x). The insets show higher magnifications of a seromucous gland and the bronchial epithelium (original magnification 200x). (B) Normal tissue adjacent to carcinoid tumor tissue with cytoplasmic OTP reactivity of the bronchial epithelium and seromucous glands (original magnification 200x), in agreement with the Human Protein Atlas (http://www.proteinatlas.org/ENSG00000171540). The inset shows cytoplasmic reactivity in macrophages (original magnification 400x). (C) Normal tissue adjacent to a carcinoid tumor showing cytoplasmic RET positivity of the bronchial epithelium and seromucous glands (original magnification 200x), in agreement with the Human Protein Atlas (http://www.proteinatlas.org/ENSG00000165731). The inset shows strong membranous RET staining in normal colon (original magnification 200x).
Table S2 from Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome
Authors: Planck Maria , Isaksson Sofi , Veerla Srinivas , Staaf Johan
Published: April 2023

Table S2 - XLSX til4 203K, Multicohort EGFR-1/2 and wt/wt-1/2 centroids
Table S1 from Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated with Patient Outcome
Authors: Planck Maria , Isaksson Sofi , Veerla Srinivas , Staaf Johan
Published: April 2023

Table S1 - PDF file 84K, Characteristics of adenocarcinoma cohorts with EGFR/KRAS mutation status and NSCLC cohorts used for treatment prediction used in the current study
Supplementary Table 1 from Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11
Authors: Drayton Ross M. , Dudziec Ewa , Peter Stefan , Bertz Simone , Hartmann Arndt , Bryant Helen E. , Catto James WF.
Published: April 2023

PDF file - 42KB, Tumour and patient information and miR-27a/b and SLC7A11 mRNA expression data from the 139 patient cohort used to generate figure 6 a, b.
Supplementary Tables 1-2 from The CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis
Authors: Zhuo Wei , Jia Lin , Song Nan , Lu Xin-an , Ding Yanping , Wang Xiaofeng , Song Xiaomin , Fu Yan , Luo Yongzhang
Published: April 2023

PDF file - 141K, S1. Primers for qRT-PCR; S2. The expression level of CXCL12 and the lymphatic vessel density in the human tissue microarray
Supplementary Figure Legends from Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11
Authors: Drayton Ross M. , Dudziec Ewa , Peter Stefan , Bertz Simone , Hartmann Arndt , Bryant Helen E. , Catto James WF.
Published: April 2023

PDF file - 37KB
Supplementary Figure 1 from Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11
Authors: Drayton Ross M. , Dudziec Ewa , Peter Stefan , Bertz Simone , Hartmann Arndt , Bryant Helen E. , Catto James WF.
Published: April 2023

PDF file - 120KB, Standalone taqman assay validation of microRNA-27a downregulation in cisplatin resistant EJ-R cells.
Supplementary Methods 1 from Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Skor Maxwell N. , Wonder Erin L. , Kocherginsky Masha , Goyal Anju , Hall Ben A. , Cai Yi , Conzen Suzanne D.
Published: April 2023

Supplementary Methods 1 - PDF file 64K, Annotated ImageJ macro for quantifying total cell numbers and apoptotic cells using digitally captured IncuCyte images
Supplementary Figure Legends from Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Skor Maxwell N. , Wonder Erin L. , Kocherginsky Masha , Goyal Anju , Hall Ben A. , Cai Yi , Conzen Suzanne D.
Published: April 2023

Supplementary Figure Legends - PDF file 104K, Supplemental figure legends 1-7
Supplementary Figure 7 from Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Skor Maxwell N. , Wonder Erin L. , Kocherginsky Masha , Goyal Anju , Hall Ben A. , Cai Yi , Conzen Suzanne D.
Published: April 2023

Supplementary Figure 7 - PDF file 126K, Representative images of clonogenic assay with MDA-MB-231 cells
Supplementary Figure 1 from CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
Authors: Banerjee Sulagna , Nomura Alice , Sangwan Veena , Chugh Rohit , Dudeja Vikas , Vickers Selwyn M. , Saluja Ashok
Published: April 2023

PDF file - 644KB, Characterizing KPC tumor initiating cells.
Supplementary Figure Legend from Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
Authors: Jones Kimberley , Vari Frank , Keane Colm , Crooks Pauline , Nourse Jamie P. , Seymour Louise A. , Gottlieb David , Ritchie David , Gill Devinder , Gandhi Maher K.
Published: April 2023

PDF file - 36K
Supplementary Figure 1 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 552K, Cluster analysis of genes essential for tumor cell survival.
Supplementary Figure 7 from Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Authors: Patwardhan Parag P. , Surriga Oliver , Beckman Michael J. , de Stanchina Elisa , Dematteo Ronald P. , Tap William D. , Schwartz Gary K.
Published: April 2023

PDF file - 48KB, Effect of AFS98, a c-Fms specific antibody, on MPNST tumor growth.
Supplementary Figure 4 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets
Authors: Stefanska Barbara , Cheishvili David , Suderman Matthew , Arakelian Ani , Huang Jian , Hallett Michael , Han Ze-Guang , Al-Mahtab Mamun , Akbar Sheikh Mohammad Fazle , Khan Wasif Ali , Raqib Rubhana , Tanvir Imrana , Khan Haseeb Ahmed , Rabbani Shafaat A. , Szyf Moshe
Published: April 2023

PDF file - 651KB, Supplementary Figure S4. Expression of RASAL2 and NENF on the protein level as determined by western blot using anti-RASAL2 (Bethyl Laboratories Inc., A302-109A) or anti-NENF (Abcam, ab74474) antibody at 1:1000 and 1:500 dilution, respectively. Protein levels were verified 48 h after first (I), second (II) or third (III) transfection of HepG2, SkHep1, and NorHep with siRNA directed to RASAL2 or NENF. Antibody to beta-actin was used as a loading control. For SkHep1 cells transfected with siRASAL2 or siNENF and for HepG2 cells transfected with siNENF, evaluation after third transfection was not possible due to the reduced cell number after three transfections.
Figure-S5 from ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Authors: Huang Hsuan-Ying , Wu Wen-Ren , Wang Yu-Hui , Wang Jun-Wen , Fang Fu-Min , Tsai Jen-Wei , Li Shau-Hsuan , Hung Hsiao-Chin , Yu Shih-Chen , Lan Jui , Shiue Yow-Ling , Hsing Chung-His , Chen Li-Tzong , Li Chien-Feng
Published: April 2023

Figure-S5 PDF file 92K, Figure-S5 ASS1 reexpression attenuates cell migration and invasiveness of myxofibrosarcoma cells. (A) Wound healing assay (left panel) reveals that the capability of wound closure is significantly impaired in both stable ASS1-transfected OH931 (upper row), NMFH-1 (middle row), and NMFH-2 (lower row) cell lines, indicating the anti-migratory function of ASS1. Experiments are performed in triplicate and results expressed as mean �} SD (Right panel). (B) Results of transwell invasion assay reveal that the capability of cell invasion is significantly impaired in both stable ASS1-transfecting OH931 (left panel) and NMFH-1 (right panel) cell lines, indicating the inhibitory role of ASS1 in invasive function of sarcoma cells
Supplementary Movie 2B from Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer
Authors: Baek Sora , Choi Chang-Min , Ahn Sei Hyun , Lee Jong Won , Gong Gyungyub , Ryu Jin-Sook , Oh Seung Jun , Bacher-Stier Claudia , Fels Lüder , Koglin Norman , Hultsch Christina , Schatz Christoph A. , Dinkelborg Ludger M. , Mittra Erik S. , Gambhir Sanjiv S. , Moon Dae Hyuk
Published: April 2023

AVI, 161K, Maximum intensity projection of 18FFSPG in a breast cancer patient (Patient 13).
Supplementary Methods and Figures 1 - 3 from B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Authors: Carpenter Robert O. , Evbuomwan Moses O. , Pittaluga Stefania , Rose Jeremy J. , Raffeld Mark , Yang Shicheng , Gress Ronald E. , Hakim Frances T. , Kochenderfer James N.
Published: April 2023

PDF file - 90K, Anti-bcma2 transduced T cells from Myeloma Patient 4 produced TNF and IFN in a BCMA-specific manner.BCMA protein in solution does not block recognition of BCMA+ target cells by anti-bcma2-transduced T cells in vitro.Human BCMA protein was detected by ELISA in the serum of NSG mice with RPMI8226 tumors, but human BCMA protein was not detected in the serum of a control mouse that did not have a tumor.
Supplementary Table 1 from Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Authors: Gold Kathryn A. , Kim Edward S. , Liu Diane D. , Yuan Ping , Behrens Carmen , Solis Luisa M. , Kadara Humam , Rice David C. , Wistuba Ignacio I. , Swisher Stephen G. , Hofstetter Wayne L. , Lee J. Jack , Hong Waun K.
Published: April 2023

PDF file - 53K, Antibodies used for immunohistochemistry.
Supplementary Figure 1 from Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Authors: Gold Kathryn A. , Kim Edward S. , Liu Diane D. , Yuan Ping , Behrens Carmen , Solis Luisa M. , Kadara Humam , Rice David C. , Wistuba Ignacio I. , Swisher Stephen G. , Hofstetter Wayne L. , Lee J. Jack , Hong Waun K.
Published: April 2023

PDF file - 45K, Consort Diagram.
Supplementary Table 8 from Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer
Authors: Sun Xuezheng , Gierach Gretchen L. , Sandhu Rupninder , Williams Tyisha , Midkiff Bentley R. , Lissowska Jolanta , Wesolowska Ewa , Boyd Norman F. , Johnson Nicole B. , Figueroa Jonine D. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Table 8 - PDF file 43K, The association of breast composition percentage with Active/Inactive subtype and mammographic density
Supplementary Figures 1 - 5, Tables 1 - 2 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Authors: Riester Markus , Werner Lillian , Bellmunt Joaquim , Selvarajah Shamini , Guancial Elizabeth A. , Weir Barbara A. , Stack Edward C. , Park Rachel S. , O'Brien Robert , Schutz Fabio A.B. , Choueiri Toni K. , Signoretti Sabina , Lloreta Josep , Marchionni Luigi , Gallardo Enrique , Rojo Federico , Garcia Denise I. , Chekaluk Yvonne , Kwiatkowski David J. , Bochner Bernard H. , Hahn William C. , Ligon Azra H. , Barletta Justine A. , Loda Massimo , Berman David M. , Kantoff Philip W. , Michor Franziska , Rosenberg Jonathan E.
Published: April 2023

PDF file - 423KB, Figure S1: Broad copy numbers at the p- and q-arms in the Spanish cohort; Figure S2: Broad copy numbers at the p- and q-arms in the DFCI cohort. (see Figure S1 for an explanation of this plot); Figure S3: These GISTIC output files show the correlation between gene number and frequency of armlevel events in the (a) Spanish cohort and the (b) DFCI cohort; Figure S4: Recurrent copy number gains in the (a) Spanish and (b) DFCI cohort. Figure S5: Recurrent deletions in the (a) Spanish and (b) DFCI cohorts (see Figure S4 for an explanation of this plot); Table S1: Significant (q-value < 0.25) GISTIC broad aberrations and their association with overall survival after start of chemotherapy (Spanish cohort); Table S2: Significant (q-value < 0.25) GISTIC broad aberrations and their association with overall survival after recurrence (DFCI cohort).
Supplementary Table 6 from Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer
Authors: Sun Xuezheng , Gierach Gretchen L. , Sandhu Rupninder , Williams Tyisha , Midkiff Bentley R. , Lissowska Jolanta , Wesolowska Ewa , Boyd Norman F. , Johnson Nicole B. , Figueroa Jonine D. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Table 6 - PDF file 52K, Participant and clinicopathologic characteristics by mammographic density measures
Supplementary Figure 6 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Authors: Riester Markus , Werner Lillian , Bellmunt Joaquim , Selvarajah Shamini , Guancial Elizabeth A. , Weir Barbara A. , Stack Edward C. , Park Rachel S. , O'Brien Robert , Schutz Fabio A.B. , Choueiri Toni K. , Signoretti Sabina , Lloreta Josep , Marchionni Luigi , Gallardo Enrique , Rojo Federico , Garcia Denise I. , Chekaluk Yvonne , Kwiatkowski David J. , Bochner Bernard H. , Hahn William C. , Ligon Azra H. , Barletta Justine A. , Loda Massimo , Berman David M. , Kantoff Philip W. , Michor Franziska , Rosenberg Jonathan E.
Published: April 2023

PDF file - 38KB, Chromosomal Instability. Analysis testing for potential confounding of pathologic stage and tissue type on chromosomal instability. Figure S6: Fraction of genome altered (FGA, 1) in both cohorts.
Supplementary Table 1 from Relationship of Mammographic Density and Gene Expression: Analysis of Normal Breast Tissue Surrounding Breast Cancer
Authors: Sun Xuezheng , Gierach Gretchen L. , Sandhu Rupninder , Williams Tyisha , Midkiff Bentley R. , Lissowska Jolanta , Wesolowska Ewa , Boyd Norman F. , Johnson Nicole B. , Figueroa Jonine D. , Sherman Mark E. , Troester Melissa A.
Published: April 2023

Supplementary Table 1 - PDF file 23K, Pearson correlation coefficient between evaluation approaches by breast composition
Supplementary Figure Legends from Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma
Authors: Liang Beibei , Chen Rui , Wang Tao , Cao Lei , Liu Yingying , Yin Fan , Zhu Minhui , Fan Xiaoyu , Liang Yingchao , Zhang Lu , Guo Yajun , Zhao Jian
Published: April 2023

PDF File - 145K, Legends for Supplementary Figures 1-5
Supplementary Table 2 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
Authors: Beard Rachel E. , Abate-Daga Daniel , Rosati Shannon F. , Zheng Zhili , Wunderlich John R. , Rosenberg Steven A. , Morgan Richard A.
Published: April 2023

XLSX file - 51K, Supplemental Table S2. Cell Lines: mel1300 mel526 mel624.38 mel888 SK-mel-23
Supplementary Figure 2 from Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non–Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
Authors: Zhang Jingchuan , Zhang Lin , Su Xinying , Li Ming , Xie Liang , Malchers Florian , Fan ShuQiong , Yin XiaoLu , Xu YanPing , Liu Kunji , Dong Zhengwei , Zhu Guanshan , Qian Ziliang , Tang Lili , Zhan Ping , Ji Qunsheng , Kilgour Elaine , Smith Paul D. , Brooks A. Nigel , Thomas Roman K. , Gavine Paul R.
Published: April 2023

PDF file - 106K, Detection of FGFR1 gene amplification in DMS114 cells using FISH analysis
Supplementary Figure 5 from Downregulation of miR-452 Promotes Stem-Like Traits and Tumorigenicity of Gliomas
Authors: Liu Liping , Chen Kun , Wu Jueheng , Shi Ling , Hu Bo , Cheng Shiyuan , Li Mengfeng , Song Libing
Published: April 2023

Overexpression of miR-452 decreases glioma cell tumorigenesis in vivo.
Supplementary Figure 3 from Downregulation of miR-452 Promotes Stem-Like Traits and Tumorigenicity of Gliomas
Authors: Liu Liping , Chen Kun , Wu Jueheng , Shi Ling , Hu Bo , Cheng Shiyuan , Li Mengfeng , Song Libing
Published: April 2023

miR-452 directly targets Bmi-1, LEF1 and TCF4.
Supplementary Figure 1 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Authors: Reis Bernardo Sgarbi , Jungbluth Achim A. , Frosina Denise , Holz Megan , Ritter Erika , Nakayama Eiichi , Ishida Toshiaki , Obata Yuichi , Carver Brett , Scher Howard , Scardino Peter T. , Slovin Susan , Subudhi Sumit K. , Reuter Victor E. , Savage Caroline , Allison James P. , Melamed Jonathan , Jäger Elke , Ritter Gerd , Old Lloyd J. , Gnjatic Sacha
Published: April 2023

- PDF file 79K, GAG-HERV-K ch22q11.23 features. Endogenous retrovirus K from chromosome 22 is located on the q11.23 region, nearby the BCR, ZDHHC8P, IGLL1 and RGL4 genes. HERV-K ch22q11.23 has GAG-PRO, POL and ENV genes flanked by LTR sequences. The GAG gene has an ORF encoding a 715aa protein that contains P10, P24 and Zinc finger domains. {delta}: deletions; I: early stop codons; --> primer binding regions; ABS: antibody binding site for monoclonal antibody TI-35 (see Supplementary Fig. S3C)
Supplementary Table Legend from MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia
Authors: de Leeuw David C. , van den Ancker Willemijn , Denkers Fedor , de Menezes Renée X. , Westers Theresia M. , Ossenkoppele Gert J. , van de Loosdrecht Arjan A. , Smit Linda
Published: April 2023

PDF file - 49K
Supplementary Figure Legend from Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma
Authors: Hui Angela B.Y. , Lin Alice , Xu Wei , Waldron Levi , Perez-Ordonez Bayardo , Weinreb Ilan , Shi Wei , Bruce Jeff , Huang Shao Hui , O'Sullivan Brian , Waldron John , Gullane Patrick , Irish Jonathan C. , Chan Kelvin , Liu Fei-Fei
Published: April 2023

PDF file - 71K
Supplementary Figure 3 from Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma
Authors: Hui Angela B.Y. , Lin Alice , Xu Wei , Waldron Levi , Perez-Ordonez Bayardo , Weinreb Ilan , Shi Wei , Bruce Jeff , Huang Shao Hui , O'Sullivan Brian , Waldron John , Gullane Patrick , Irish Jonathan C. , Chan Kelvin , Liu Fei-Fei
Published: April 2023

PDF file - 65K, Comparison of differential miRNA expression levels by p16 IHC and HPV16 ISH
Supplemental Figure 3 from Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy
Authors: Bid Hemant K. , London Cheryl A. , Gao Jin , Zhong Haihong , Hollingsworth Robert E. , Fernandez Soledad , Mo Xiaokui , Houghton Peter J.
Published: April 2023

Supplemental Figure 3 PDF file 121K, Photomicrograph
Supplementary Figure 1 from Potentially Prognostic miRNAs in HPV-Associated Oropharyngeal Carcinoma
Authors: Hui Angela B.Y. , Lin Alice , Xu Wei , Waldron Levi , Perez-Ordonez Bayardo , Weinreb Ilan , Shi Wei , Bruce Jeff , Huang Shao Hui , O'Sullivan Brian , Waldron John , Gullane Patrick , Irish Jonathan C. , Chan Kelvin , Liu Fei-Fei
Published: April 2023

PDF file - 53K, Survival analysis of the 88 analyzed OPC patients
Supplementary Figure 2 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Authors: Anitei Maria-Gabriela , Zeitoun Guy , Mlecnik Bernhard , Marliot Florence , Haicheur Nacilla , Todosi Ana-Maria , Kirilovsky Amos , Lagorce Christine , Bindea Gabriela , Ferariu Dan , Danciu Mihai , Bruneval Patrick , Scripcariu Viorel , Chevallier Jean-Marc , Zinzindohoué Franck , Berger Anne , Galon Jérôme , Pagès Franck
Published: April 2023

PDF file - 104KB, Immunoscore.
Supplementary Figure 3 from Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Authors: Shi Yu , Chen Cong , Zhang Xia , Liu Qing , Xu Jin-Ling , Zhang Hua-Rong , Yao Xiao-Hong , Jiang Tao , He Zhi-Cheng , Ren Yong , Cui Wei , Xu Chuan , Liu Ling , Cui You-Hong , Yu Shi-Zhu , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

PDF file - 546K, Supplementary Fig. S3. Identification of PIK3CD as a target by miR-663.
Supplementary Figure 2 from Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Authors: Shi Yu , Chen Cong , Zhang Xia , Liu Qing , Xu Jin-Ling , Zhang Hua-Rong , Yao Xiao-Hong , Jiang Tao , He Zhi-Cheng , Ren Yong , Cui Wei , Xu Chuan , Liu Ling , Cui You-Hong , Yu Shi-Zhu , Ping Yi-Fang , Bian Xiu-Wu
Published: April 2023

PDF file - 747K, Supplementary Fig. S2. The effects of miR-663 on GBM cells.
Related Article from Can Stroma Reaction Predict Cancer Lethality?
Authors: Freeman Michael R. , Li Quanlin , Chung Leland W.K.
Published: April 2023

Related Article from Can Stroma Reaction Predict Cancer Lethality?
Supplementary Table 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Authors: Win Thida , Miles Kenneth A. , Janes Sam M. , Ganeshan Balaji , Shastry Manu , Endozo Raymondo , Meagher Marie , Shortman Robert I. , Wan Simon , Kayani Irfan , Ell Peter J. , Groves Ashley M.
Published: April 2023

Supplementary Table 1 - PDF file 38K, Data to supplement Kaplan Meier curve in Supplementary Figure2
Supplementary Figure 1 from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Authors: Win Thida , Miles Kenneth A. , Janes Sam M. , Ganeshan Balaji , Shastry Manu , Endozo Raymondo , Meagher Marie , Shortman Robert I. , Wan Simon , Kayani Irfan , Ell Peter J. , Groves Ashley M.
Published: April 2023

Supplementary Figure 1 - PDF file 49K, The 2-D forms of the LoG filter in the spatial and frequency domain at filter value of 2.0
Supplementary Figure 2 from Alternative Cleavage and Polyadenylation during Colorectal Cancer Development
Authors: Morris Adam R. , Bos Arnold , Diosdado Begoña , Rooijers Koos , Elkon Ran , Bolijn Anne S. , Carvalho Beatriz , Meijer Gerrit A. , Agami Reuven
Published: April 2023

PDF file - 99K, APA events during colon cancer progression. A. UTR-APA and CR-APA events. B. 3'UTR shortening versus lengthening in UTR-APA
Supplementary Figure 1 from Alternative Cleavage and Polyadenylation during Colorectal Cancer Development
Authors: Morris Adam R. , Bos Arnold , Diosdado Begoña , Rooijers Koos , Elkon Ran , Bolijn Anne S. , Carvalho Beatriz , Meijer Gerrit A. , Agami Reuven
Published: April 2023

PDF file - 155K, Sequencing statistics
CCR Translation for This Article from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Authors: Tagawa Scott T. , Milowsky Matthew I. , Morris Michael , Vallabhajosula Shankar , Christos Paul , Akhtar Naveed H. , Osborne Joseph , Goldsmith Stanley J. , Larson Steve , Taskar Neeta Pandit , Scher Howard I. , Bander Neil H. , Nanus David M.
Published: April 2023

CCR Translation for This Article from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Supplementary Table 1 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 59K, Patient demographic and pathologic variables in blood monocyte analysis.
Supplementary Figure 7 from Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Authors: Flanigan Sara A. , Pitts Todd M. , Newton Timothy P. , Kulikowski Gillian N. , Tan Aik Choon , McManus Martine C. , Spreafico Anna , Kachaeva Maria I. , Selby Heather M. , Tentler John J. , Eckhardt S. Gail , Leong Stephen
Published: April 2023

Supplementary Figure 7 - PDF file 104K, Cell Cycle Analysis
Supplementary Figure 5 from Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Authors: Sanford Dominic E. , Belt Brian A. , Panni Roheena Z. , Mayer Allese , Deshpande Anjali D. , Carpenter Danielle , Mitchem Jonathan B. , Plambeck-Suess Stacey M. , Worley Lori A. , Goetz Brian D. , Wang-Gillam Andrea , Eberlein Timothy J. , Denardo David G. , Goedegebuure Simon Peter , Linehan David C.
Published: April 2023

PDF - 26K, Inflammatory monocytes persist in the blood of PC patients undergoing chemotherapy.
Supplementary Table 2 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
Authors: Xu Ye , Xu Qinghua , Yang Li , Ye Xun , Liu Fang , Wu Fei , Ni Shujuan , Tan Cong , Cai Guoxiang , Meng Xia , Cai Sanjun , Du Xiang
Published: April 2023

PDF file - 70K, Signature genes enriched in Gene Ontology and KEGG pathway.
Supplementary Table 1 from Identification and Validation of a Blood-Based 18-Gene Expression Signature in Colorectal Cancer
Authors: Xu Ye , Xu Qinghua , Yang Li , Ye Xun , Liu Fang , Wu Fei , Ni Shujuan , Tan Cong , Cai Guoxiang , Meng Xia , Cai Sanjun , Du Xiang
Published: April 2023

PDF file - 58K, The table list primer sequences for 18 signature genes and 3 reference genes.
Supplementary Methods from Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Authors: Broniscer Alberto , Baker Sharyn D. , Wetmore Cynthia , Pai Panandiker Atmaram S. , Huang Jie , Davidoff Andrew M. , Onar-Thomas Arzu , Panetta John C. , Chin Thomas K. , Merchant Thomas E. , Baker Justin N. , Kaste Sue C. , Gajjar Amar , Stewart Clinton F.
Published: April 2023

PDF file - 93K, Supplemental data provides details about the methods to obtain pharmacokinetic and pharmacodynamic studies.
Supplemental Figure S1 from A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Authors: Saridaki Zenia , Weidhaas Joanne B. , Lenz Heinz-Josef , Laurent-Puig Pierre , Jacobs Bart , De Schutter Jef , De Roock Wendy , Salzman David W. , Zhang Wu , Yang Dongyun , Pilati Camilla , Bouché Olivier , Piessevaux Hubert , Tejpar Sabine
Published: April 2023

(A) Median progression free survival and (B) median overall survival, according to the KRAS 3'-UTR LCS6 SNP genotype status in patients treated with anti-EGFR moAbs monotherapy or in combination with chemotherapy as salvage treatment.
Supplementary Figure 1 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 114KB, Expression of Akt and PTEN in OV-90 and TOV-21G cells.
Supplementary Materials and Methods from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Authors: Dolman M. Emmy M. , Poon Evon , Ebus Marli E. , den Hartog Ilona J.M. , van Noesel Carel J.M. , Jamin Yann , Hallsworth Albert , Robinson Simon P. , Petrie Kevin , Sparidans Rolf W. , Kok Robbert J. , Versteeg Rogier , Caron Huib N. , Chesler Louis , Molenaar Jan J.
Published: April 2023

Supplementary Materials and Methods. Detailed protocol for cell culturing, in vitro and in vivo Western Blotting, in vitro FACS analysis, in vitro synergy studies and in vivo immunohistochemistry
Supplementary Figure Legends from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
Authors: Dolman M. Emmy M. , Poon Evon , Ebus Marli E. , den Hartog Ilona J.M. , van Noesel Carel J.M. , Jamin Yann , Hallsworth Albert , Robinson Simon P. , Petrie Kevin , Sparidans Rolf W. , Kok Robbert J. , Versteeg Rogier , Caron Huib N. , Chesler Louis , Molenaar Jan J.
Published: April 2023

Legends for supplementary figures S1-S8.
Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Authors: Di Cosimo Serena , Sathyanarayanan Sriram , Bendell Johanna C. , Cervantes Andrés , Stein Mark N. , Braña Irene , Roda Desamparados , Haines Brian B. , Zhang Theresa , Winter Christopher G. , Jha Sharda , Xu Youyuan , Frazier Jason , Klinghoffer Richard A. , Leighton-Swayze Ann , Song Yang , Ebbinghaus Scot , Baselga José
Published: April 2023

Supplementary Figure 4. Responder biomarker hypothesis for ridaforolimus and dalotuzumab?based therapy
Supplementary Figure 3 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
Authors: Di Cosimo Serena , Sathyanarayanan Sriram , Bendell Johanna C. , Cervantes Andrés , Stein Mark N. , Braña Irene , Roda Desamparados , Haines Brian B. , Zhang Theresa , Winter Christopher G. , Jha Sharda , Xu Youyuan , Frazier Jason , Klinghoffer Richard A. , Leighton-Swayze Ann , Song Yang , Ebbinghaus Scot , Baselga José
Published: April 2023

Supplementary Figure 3. Change in Ki67 levels with ridaforolimus and dalotuzumab combination therapy
Data Supplement from Demethylating Drugs as Novel Analgesics for Cancer Pain
Authors: Viet Chi T. , Dang Dongmin , Ye Yi , Ono Kentaro , Campbell Ronald R. , Schmidt Brian L.
Published: April 2023

Supplementary description of methods include details on the mouse xenograft model, in situ hybridization, and the beta-endorphin ELISA.
Supplementary Table 4 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 157K, Candidate genes for RNAi screen
Supplementary Figures 1-5 from Identification of Galanin and Its Receptor GalR1 as Novel Determinants of Resistance to Chemotherapy and Potential Biomarkers in Colorectal Cancer
Authors: Stevenson Leanne , Allen Wendy L. , Turkington Richard , Jithesh Puthen V. , Proutski Irina , Stewart Gail , Lenz Heinz-Josef , Van Schaeybroeck Sandra , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

PDF file - 355K, supplementary figures S1. RNAi screen S2. QPCR S3. Cell viability analysis S4. Apoptosis analysis S5. FLIPL
Supplementary Figure 1 from Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma
Authors: Heemann Christina , Kreuz Markus , Stoller Irene , Schoof Nils , von Bonin Frederike , Ziepert Marita , Löffler Markus , Jung Wolfram , Pfreundschuh Michael , Trümper Lorenz , Kube Dieter
Published: April 2023

PDF file, 139KB, Overall and Event free survival of patients suffering from T-cell Non-Hodgkin lymphoma in relation to circulating serum levels of sTNFRI, IL-10 and sIL-4R. The survival curves (Kaplan-Meier plots) show a comparison of the OS (A,C,E) and EFS (B,D,F) of T-NHL patients with circulating serum levels of sTNFRI (A,B), IL-10 (C,D) and sIL-4R (E,F). The respective threshold used to define high and low producers is indicated in the figure legend (lower left). For high producers of sTNFRI (B) and sIL-4R (F) an insignificant trend for shorter EFS was observed (p=0.0886 and p=0.333). The other survival curves show no trends for associations of serum levels and survival periods. P refers to the log-rank test. Patients at risk represents the number of patients which still can develop an event (OS or EFS) at defined time points.
Supplemental Table S1 from A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Authors: Saito Motonobu , Shiraishi Kouya , Matsumoto Kenji , Schetter Aaron J. , Ogata-Kawata Hiroko , Tsuchiya Naoto , Kunitoh Hideo , Nokihara Hiroshi , Watanabe Shun-ichi , Tsuta Koji , Kumamoto Kensuke , Takenoshita Seiichi , Yokota Jun , Harris Curtis C. , Kohno Takashi
Published: April 2023

Clinicopathological characteristics of study populations.
Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Authors: Srivastava Raghvendra M. , Lee Steve C. , Andrade Filho Pedro A. , Lord Christopher A. , Jie Hyun-Bae , Davidson H. Carter , López-Albaitero Andrés , Gibson Sandra P. , Gooding William E. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 466K, Enhancement of DC maturation by cetuximab-activated NK cells.
Supplementary Figures 1 - 6 from Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer
Authors: Singh Anand Kamal , Chandra Nishi , Bapat Sharmila A.
Published: April 2023

Supplementary Fig.1. Flow chart of approach for identification of progression associated biomarkers based on differential promoter methylation Supplementary Fig.2a. Venn diagram representing hypo- and hyper-methylated genes in the A4 progression model; b. Heat map representation of differentially expressed genes during A4 progression; c. Heat map representation of differentially expressed genes between Group1 (Grades I & II) and Group2 (Grade III) TCGA ovarian cancer tumors; d. Commonly regulated 25 genes during A4 and TCGA tumor progression through methylation and expression analyses; e. Functional annotation of differential progression associated genes Supplementary Fig.3a. Heat map representing mRNA expression pattern of genes enriched exclusively with histone marks during A4 progression model (values are in ratios of A4T/A4P because of comparative 2-color microarray); b. DAVID assigned different functional annotation to these genes. DAVID assigned different functional annotation to these genes. Supplementary Fig.4a. Quantitation of differential apoptosis mediated by epigenetic drugs during A4 progression (early apoptosis + late apoptosis); b-i. Spheroid formation capability of A4T cells (Day 12) following exposure to epigenetic drugs at their respective IC50 concentration and 3 days recovery; b-ii. Representative images of such A4T cell spheroids (20x, scale-100μm). c-i. Epigenetic drug regimes in studying effects of epigenetic drugs on A4T xenografts; c-ii. Tumor regression following drug exposure - controls (left) and treated tumors (right); d. Schematic for deriving the representative FACS profiles and quantification of subsets at various levels (Levels 1,2,3 represent PKH hierarchy, ploidy and cell cycle respectively). This resolution was used in analyzing the effects of epigenetic drugs on the background of tumor cell heterogeneity; (*p<0.05, **p< 0.01, ***p<0.001) Supplementary Fig.5. Phase contrast images representing functionality of different A4 xenograft sub-fractions following 5-Aza-dC treatment Supplementary Fig.6a. Expression modulation of epigenetic biomarkers following treatment with a.i.5-Aza-dC, a.ii.TSA, a.iii.Curcumin, a.iv.CBB1007, data generated as fold-change relative to control after normalization with beta-actin, fold-change > 1.5 (up-regulation) identified PTGIS as a biomarker for 5-Aza-dC and TSA, RXR-gamma for CBB1007 treatments while fold-change < 0.5 (down-regulation) identified MEST as a biomarker for curcumin treatment. b. Immunofluorscence imaging of associated biomarkers of each epigenetic drug in control and treated A4T cells. c. Immunofluorescence staining of PTGIS in spheroids formed by different tumor fractions based on the regenerative (PKH) hierarchy following 5-Aza-dC treatment. d. Frequency of cells in G0 phase after d.i. 5-Aza-dc/TSA d.ii. Curcumin d.iii. CBB1007 treatments in A4-T xenografts, *p<0.05, **p< 0.01, ***p<0.001.
Supplementary Figures 1 - 4, Table 1 from Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Authors: McNeel Douglas G. , Becker Jordan T. , Eickhoff Jens C. , Johnson Laura E. , Bradley Eric , Pohlkamp Isabel , Staab Mary Jane , Liu Glenn , Wilding George , Olson Brian M.
Published: April 2023

PDF file - 729KB, Supplementary Table 1: Adverse events. Supplementary Figure 1: Patient allocation. Supplementary Figure 2: DNA immunization elicits PAP-specific cellular immune responses. Supplementary Figure 3: Immune responses to PSA and tetanus evaluated by intracellular cytokine staining. Supplementary Figure 4: Immune responses to PAP, PSA and tetanus evaluated by cytokine secretion.
Data Supplement from PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Authors: Rahmani Mohamed , Aust Mandy Mayo , Benson Elisa C. , Wallace LaShanale , Friedberg Jonathan , Grant Steven
Published: April 2023

Cell lines and primary antibodies.
Supplementary Table S3 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

miRNA differentially expressed in metastatic ARCaPM prostate cancer cells and non-metastatic ARCaPE prostate cancer cells by multiplexed real time PCR analysis. miRNA in bold are in the DLK1-DIO3 mega-cluster.
Supplementary Table S2 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

Global miRNA expression, represented as Ct values assayed by multiplexed qRT-PCR analysis in ARCaPE and ARCaPM PCa EMT bone metastatic model.
Supplementary Table 1 from Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Authors: Pan Ke , Guan Xun-Xing , Li Yong-Qiang , Zhao Jing-Jing , Li Jian-Jun , Qiu Hui-Juan , Weng De-Sheng , Wang Qi-Jing , Liu Qing , Huang Li-Xi , He Jia , Chen Shi-Ping , Ke Miao-La , Zeng Yi-Xin , Xia Jian-Chuan
Published: April 2023

PDF file - 119KB, Characteristics of patient who received CIK cell treatment.
Supplementary Figure S4 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

A, miR-409-5p and miR-409-3p in exosomes from ARCaPE and ARCaPM PCa cells measured by qRT-PCR. B, miR-409-5p levels in exosomes from ARCaPM-C and ARCaPM-409-5pi PCa cells measured by qRT-PCR.
Supplementary Tables 4 - 7 from Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Authors: Eng Lawson , Azad Abul Kalam , Habbous Steven , Pang Vincent , Xu Wei , Maitland-van der Zee Anke H. , Savas Sevtap , Mackay Helen J. , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file, 113K, Supplementary Tables 4-7: These tables summarize in detail, the prognostic associations of VEGF pathway polymorphisms with drug response/survival on survival parameters.